Anthropic CEO predicts AI will eliminate major diseases within a decade

Anthropic CEO Dario Amodei has a timeline for ending some of humanity’s oldest enemies. He predicts that artificial intelligence will eliminate cancer, Alzheimer’s, heart disease, and mental illness within a decade.

He made the claim in an IPO roadshow video on November 10, 2026.

What Amodei is actually claiming

This is not a new position for him. Since at least October 2024, Amodei has argued that powerful AI could deliver 50 to 100 years of biomedical progress in just 5 to 10 years.

The list is not modest. Cancer, Alzheimer’s, heart disease, and mental illness are among the most researched conditions in medicine, and each is really a family of conditions rather than a single problem.

Anthropic is putting money behind the bet

Amodei’s optimism comes with a business strategy attached. Anthropic has been building out its work at the intersection of AI and biology through a series of partnerships and deals.

The company has partnered with biotech firms including BigHat Biosciences and pharmaceutical giant Bristol Myers Squibb. It has also acquired Mithril Medicine, a startup focused on treating rare muscular dystrophies.

Anthropic’s drug discovery programs reportedly target a range of conditions:

• Cancer
• Food allergies
• Rare diseases
• Childhood variants of muscular dystrophy

Amodei’s motivation is also personal. He has said he survived early-stage cancer himself. He has also cited his father’s death from a treatable illness as a driving force behind his work in AI and medicine.

The skeptics have entered the chat

Karl Lauterbach, Germany’s former health minister, has acknowledged that AI holds real potential for drug discovery. But he has argued that a decade is not enough time, given how complex clinical trials and regulatory approvals are.

AI researcher Gary Marcus has been more blunt. He and other critics have described 5 to 10 year cure timelines as “wildly off-base,” with some calling them “naive” and even “impossible” because of how clinical trials work.

Why the timing raises eyebrows

Bold predictions from tech founders are nothing new. Making one during an IPO roadshow, however, puts it in a different light.

A roadshow exists to convince investors that a company’s future is worth buying into. To be fair to Amodei, the claim is consistent with what he has been saying since 2024. This is not a forecast invented for the occasion.